Search

Displaying results 7921 - 7930 of 9680 in total
  1. Drug

    R343

    go.drugbank.com/drugs/DB06316
    Investigational

    R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.

  2. Drug

    R-348

    go.drugbank.com/drugs/DB06321
    Investigational

  3. Drug

    Carotuximab

    go.drugbank.com/drugs/DB06322
    Investigational

  4. Drug

    Pegpleranib

    go.drugbank.com/drugs/DB06325
    Investigational

  5. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

  6. Drug

    AR-9281

    go.drugbank.com/drugs/DB06345
    Investigational

    AR-9281 inhibits soluble epoxide hydrolase.

  7. Drug

    Cenisertib

    go.drugbank.com/drugs/DB06347
    Investigational

    Cenisertib is an aurora kinase inhibitor.

  8. Drug

    Tezampanel

    go.drugbank.com/drugs/DB06354
    Investigational

    Tezampanel is an AMPA receptor antagonist.

  9. Drug

    Lucatumumab

    go.drugbank.com/drugs/DB06360
    Investigational

  10. Drug

    Pertuzumab

    go.drugbank.com/drugs/DB06366
    ApprovedInvestigational

    Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.